The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal

Published:2017-05-03 Issue:6 Volume:177 Page:1000-1007
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kayastha Gyan K.¹,Ranjitkar Nora¹,Gurung Radha¹,KC Raj Kumar¹,Karki Sanjit¹,Shrestha Roshan¹,Rajbhandari Piyush¹,Thapa Raj K.¹,Poudyal Buddhi¹,Acharya Paras¹,Roberts David J.²³,Hayes Bruce¹,Zimmerman Mark¹,Basnyat Buddha¹⁴^ORCID

Affiliation:

1. Patan Academy of Health Science; Patan Hospital; Kathmandu Nepal

2. National Health Service Blood and Transplant; John Radcliffe Hospital; Oxford UK

3. Radcliffe Department of Medicine; John Radcliffe Hospital; Oxford UK

4. Oxford University Clinical Research Unit-Nepal; Centre for Tropical Medicine and Global Health; University of Oxford; Oxford UK

Funder

government of Nepal

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14683/fullpdf

Reference23 articles.

1. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia;Apperley;The Lancet Oncology,2007

2. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet;Baccarani;Blood,2006

3. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

4. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis;Branford;Blood,2003

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study;BMC Research Notes;2024-04-20

2. Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation;Chemical Biology & Drug Design;2020-10-29

3. Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells;IRAN J BASIC MED SCI;2019

4. Epigenetic regulation of HOTAIR in advanced chronic myeloid leukemia;Cancer Management and Research;2018-11

5. Outcomes of 219 chronic myeloid leukaemia patients with additional chromosomal abnormalities and/or tyrosine kinase domain mutations;International Journal of Laboratory Hematology;2018-10-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3